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erial Measurements
f Plasma B-Type
atriuretic Peptides
hat Do They Tell Us?*
. Mark Richards, MD, PHD, DSC, FRCP, FRACP
hristchurch, Canterbury, New Zealand
irculating B-type natriuretic peptides (BNP and N-
erminal part of the pro-B-type natriuretic peptide
NT-proBNP]) increase in proportion to cardiac dysfunc-
ion, and plasma concentrations are powerful independent
redictors of outcome across the spectrum of cardiovascular
isease. Most reports underpinning the prognostic utility of
lasma B-type peptides rely on analyses derived from single
easurements per study participant. Such isolated measure-
ents improve risk stratification at any time during pro-
ression of chronic heart failure (CHF). Less is known
bout additional information to be gained from serial
eptide measurements. Changes in either BNP or NT-
roBNP over brief periods are related to subsequent out-
omes in both acute coronary syndromes and acute decom-
ensated heart failure (HF) (1,2). Changes in NT-proBNP
ver months predict outcome in advanced HF (3). The
elationship between changes in peptide levels over longer
ntervals with outcomes in a large group with stable CHF
as been explored for BNP (4) but not NT-proBNP.
See page 997
In this issue of the Journal, Masson et al. (5) examined the
rognostic value of changes in NT-proBNP between base-
ine and 4 months in 1,742 patients randomized to the
lacebo arm of the Val-HeFT (Valsartan Heart Failure
rial) study. Changes in NT-proBNP expressed as abso-
ute, percent, or categorical change were related to subse-
uent mortality. Absolute change in plasma NT-proBNP in
uartiles (Q) showed a U-shaped relationship to subsequent
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
From the Christchurch School of Medicine and Health Sciences, Department of
edicine, University of Otago, Christchurch, Canterbury, New Zealand. Dr.
ichards has had consultancy connections with both Biosite, who markets a B-typer
atriuretic peptide assay, and Roche Diagnostics, who sells the N-terminal part of the
ro-B-type natriuretic peptide assay.ortality (15.1%, 8.3%, 11.5%, and 26.4% in Q1 to Q4,
espectively), whereas mortality increased incrementally
cross quartiles of percent change in NT-proBNP (from
.2% in Q1 to 21.5% in Q4). In a third approach,
utcomes were assessed according to categorical changes
f NT-proBNP. In patients with results below the nomi-
ated threshold (1,078 pg/ml) at baseline and 4 months
52% of patients), with values above decreasing to below
7.2%), below increasing to above (6.5%), and with both
alues above the threshold (34%), mortality rates were 8.9%,
.2%, 21.1%, and 25.7%, respectively. Multivariable analysis
ncluding adjustment for age, body mass index, renal func-
ion, etiology, New York Heart Association functional
lass, left ventricular function, and baseline NT-proBNP
ndicated categories were independently associated with
ortality.
This report is the most recent in a series arising from the
al-HeFT neurohormonal substudy. The Val-HeFT study
howed BNP to be prognostically superior to several other
ecognised neurohormonal markers of risk in HF, including
orepinephrine, renin activity, aldosterone, and endothelin
6). In a head-to-head comparison of BNP and NT-
roBNP including 3,916 Val-HeFT study participants (7),
aseline BNP and NT-proBNP were powerfully and simi-
arly related to both mortality and risk of admission with
ecompensated HF independent of, and more strongly
han, any of a range of pertinent predictive demographic,
linical, and echocardiographic variables.
From results in 4,305 patients, Anand et al. (8) reported
n association between mortality and both baseline BNP
9.7%, 14.3%, 20.7%, and 32.4% in Q1 to Q4, respectively)
nd percent change (13.6%, 15.5%, 15.1%, and 19.1%, in
1 to Q4, respectively) in BNP. Subsequently, Masson
t al. (4) assessed categorical change about the baseline
edian level of BNP (97 pg/ml). Results from 3,740
atients indicated categorical divisions of low¡low,
igh¡low, low¡high, and high¡high in the 4-month
nterval were associated with 2-year mortalities of 7.9%,
2.8%, 22.7%, and 25.4%, respectively; these are highly
omparable with rates (8.9%, 7.2%, 21.1%, and 25.7%)
eported currently for categorical shifts in NT-proBNP
evels (5).
Taken together, the Val-HeFT study experience indi-
ates that changes in either BNP or NT-proBNP over
onths are predictive of outcomes in chronic HF. This
ffers the prospect of several applications, including moni-
oring of cardiac compensation and guidance of HF therapy,
election of higher-risk subjects for recruitment to thera-
eutic trials (improving power and reducing requisite sam-
le size), and potentially providing a reliable surrogate index
f efficacy of new treatments.
However, it remains debatable whether changes in pep-
ide levels offer significant practical advantages over single
easurements. Within the current report, the ascending
isk of subsequent mortality according to the baseline
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September 16, 2008:1004–5 Editorial Commentuartile of NT-proBNP levels (7.8% increasing to 25.3%
rom Q1 to Q4) suggests similar discrimination to that
erived from categorical shifts (7.2% increasing to 25.7%
isk). Absolute NT-proBNP values at 4 months outper-
ormed baseline values, as well as both absolute and per-
entage change in prediction of all-cause mortality at 24
onths by receiver-operator analysis. The investigators do not
resent a multivariable model assessing the prognostic power
f categorical shift independent of 4-month NT-proBNP
alues, nor do they report mortality by quartile of 4-month
T-proBNP levels. It remains possible that the best single
ndicator of subsequent outcomes (and the most practical tool
or the applications outlined above) is simply the single most
ecently available measurement of BNP or NT-proBNP.
The categorical threshold value of 1,078 pg/ml was
erived from receiver-operator analysis of the optimal
T-proBNP value for discriminating risk of later mortality,
 value that can only be established once mortality over
ollow-up has occurred. Clearly this is not a value that can
e discerned prospectively. The earlier Val-HeFT study
eport assessing categorical shifts of BNP used the median
aseline level of BNP (97 pg/ml), and such values would of
ourse be available from the outset during follow-up of any
iven cohort of chronic HF patients. Nevertheless, it is
nlikely that categorical shifts around threshold values
f approximately 100 and 1,000 pg/ml for BNP and
T-proBNP, respectively, can be practically or uniformly
pplied to individuals or even to other cohorts with HF.
ntuitively, an individual patient with values increasing from
ust below to barely above a threshold seems at less risk than
nother with NT-proBNP increasing from a similar initial
alue to a markedly higher final level. Yet both patients
how the same categorical shift and may be lumped together
ith same apparent mortality risk. Consideration of percent
hanges would seem less prone to this weakness.
The BNP and NT-proBNP values of 100 and 1,000
g/ml, respectively, are higher than median levels observed
n acute coronary syndromes (1) and lower than those in
cute decompensated HF (2) or severe advanced HF (3).
urther, different peptide immunoassays will yield different
umerical values and coefficients of variation. Hence, cate-
orical thresholds may need to be set for each validated
mmunoassay and separately for defined patient popula-
ions. This may limit the clinical application of such an
pproach.
The Val-HeFT study participants included only those
ith left ventricular ejection fraction 40% and left ven-
ricular internal dimension in diastole of 2.9 cm2/m2 in
ssociation with stable and symptomatic HF while on
rescribed HF therapy. The current report is further con-
ned to patients within the placebo limb of the Val-HeFT
rial, and therefore does not address the potential influence
f valsartan on relationships between peptide and prognosis.
his issue has been addressed with respect to BNP in
K
previous reports from the Val-HeFT study (4,8) and does
ot seem to confound the relationship. Nevertheless, appro-
riate threshold values may vary according to acuity of HF
nd the presence or absence of established drug treatment,
reserved ejection fraction, renal dysfunction, and/or other
emographic and clinical variables. Further studies will be
equired to comprehensively determine the prognostic util-
ty of serial measures of B-type peptides in defined sub-
roups of the overall HF population. Investigators under-
aking cohort studies or therapeutic trials in HF should be
ncouraged to incorporate serial neurohormonal measure-
ents in study designs.
Finally, the prognostic utility of changes in B-type
eptide levels will be enhanced by proper integration with
ther known markers of prognosis. Combining cardiac
maging with cardiac peptide measurements to better define
rognosis seems to hold particular promise. Notably, the
al-HeFT study incorporated serial echocardiography, pro-
iding the opportunity to undertake such an analysis (9).
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